Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 359

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 359
---
 matching contributions to deferrals made by participants.

17.Segment Reporting

The Company has reportable segment relating to the discovery and development of novel orally bioavailable, small molecule therapies across a broad range of diseases driven by STAT3 with high unmet need.

The Company’s CODM, its Chief Executive Officer and Chief Financial Officer, manages the Company’s operations on company-wide level for the purposes of allocating resources. The key measure of segment profit or loss that the CODM uses to allocate resources and assess financial performance is the Company’s net loss, which is utilized to evaluate the progress of its research and development programs and other expense categories. The CODM makes decisions using this information on a company-wide basis.

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under GAAP, to the Company’s net loss in the condensed statements of operations and comprehensive loss (in thousands):

| ​                                                    
 ​                                                    
 ​                                                    
 Direct research and development expenses by program: 
 TTI-101:                                             | ​ 
 ​ | ​                                    
 For the Three Months Ended March 31, 
 2025                                 
 ​                                    
 ​                                    |      ​ | ​ 
 ​ | ​    
 2024 
 ​    
 ​    |      ​ |
|:-----------------------------------------------------|:--|:-------------------------------------|-------:|:--|:-----|-------:|
| HCC                                                  | ​ | $                                    |    437 | ​ | $    |  1,417 |
| IPF                                                  | ​ |                                      |  1,033 | ​ |      |    616 |
| mBC                                                  | ​ |                                      |      — | ​ |      |    210 |
| Pre-clinical, CMC, and other (unallocated) (1)       | ​ |                                      |    175 | ​ |      |    356 |
| TTI-109                                              | ​ |                                      |    358 | ​ |      |    216 |
| Unallocated research and development expense:        | ​ |                                      |      — | ​ |      |        |
| Personnel costs                                      | ​ |                                      |    858 | ​ |      |    795 |
| Consultant fees and other costs (2)                  | ​ |                                      |    250 | ​ |      |    111 |
| General and administrative expense:                  | ​ |                                      |        | ​ |      |        |
| Personnel costs